LAUSR

Bacteria of the Streptomyces genus are well-known producers of secondary metabolites of high medical value. They contributed nearly 60% of current antibiotics (i.e., vancomycin, daptomycin and tetracycline), as well as antifungals, antiparasitics (avermectins), anticancer drugs (doxorubicin), immunosuppressants and others [1]. Therefore, in the past several decades, Streptomyces bacteria or the therein involved biosynthetic pathways have long been the central topic of strain improvement, metabolic engineering, and bioengineering. Much of this research has focused on regulatory elements; however, it has been a challenge due to the complex regulatory network that controls Streptomyces secondary metabolism and its complex fungus-like morphological differentiation [2]. On agar plates, production of secondary metabolites coincides with the switch from vegetative growth (substrate mycelium) to aerial mycelium hyphae and subsequent spore formation, whereas in a liquid culture, early stationary phase when cells stop growing marks the initiation of secondary metabolism. In addition to regulatory targets, others have attempted to re-wire the energy flux to direct more substrates from primary metabolism to secondary metabolism. All secondary metabolites are built upon substrates from the primary metabolism, such as acetyl-CoA, amino acids, isoprenoids, or lipids. A groundbreaking work from Drs. Lixin Zhang and Wensheng Xiang laboratories was recently published in Nature Biotechnology [3], in which they unambiguously demonstrated triacylglycerols (TAGs) as the carbon source for polyketide production in Streptomyces coelicolor A3(2), the model strain of the genus. Polyketides, a large group of structurally diverse secondary metabolites found in streptomycetes and many other microorganisms, are produced by polyketide synthases (PKSs) in an assembly line-like manner which incorporates a two-carbon unit per reaction or elongation step [4]. Acetyl-CoA and its derivative malonyl-CoA are often the starting unit and the extension substrate, respectively. Acetyl-CoA, a product of glucose catabolism, is a central substrate for almost all primary metabolic processes, such as the TCA cycle and lipid synthesis (Fig. 1), it also serves as a major precursor for secondary metabolism. For a long time, sugar (i.e., glucose) has been regarded as the carbon source for polyketide biosynthesis, although few studies suggested a potential link between lipid degradation and antibiotic production, such as spiramycin [5] and actinorhodin (ACT) [6,7]. Unlike other bacteria, TAGs is the major form of lipids accumulated in Streptomyces strains, accounting for up to 60% of total lipids during the late stationary phase [8,9]. The S. ambofaciens mutant NSA205 (ADS205, Spi), which harbors an amplified DNA sequence ADS205, does not produce spiramycin and is largely depleted in the production of both phospholipids and TAGs. Its derivative NSA228 (ADS205, Spi) which lacks ADS205 restored spiramycin production. Authors also founded that the lipid production in NSA228 was globally restored to wild-type levels, indicating a potential role of lipids in antibiotic production [5]. An open reading frame orfPS in ADS205 likely encodes a PKS. Amplification of orfPS in NSA205 may cause competition for the same precursor acetyl-CoA between fatty acid synthesis or other PKS pathways. Via the studies of ppk mutants, a similar role of TAGs was also noted for the production of the blue-pigmented polyketide antibiotic ACT in S. coelicolor and S. lividans [6,7]. Ppk modulates the ATP/ADP metabolism in streptomycetes acting either as a polyphosphate kinase (ATP